PMID- 32048238
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2199-1154 (Print)
IS  - 2198-9788 (Electronic)
IS  - 2198-9788 (Linking)
VI  - 7
IP  - 2
DP  - 2020 Jun
TI  - Impact of Adverse Events on the Progression-Free Survival of Patients with 
      Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter 
      Retrospective Study.
PG  - 141-149
LID - 10.1007/s40801-020-00179-7 [doi]
AB  - BACKGROUND AND OBJECTIVE: Experience of the use of lenvatinib (LEN) in the 
      clinical setting remains limited. We conducted this study to elucidate the 
      factors associated with progression-free survival (PFS) in patients with advanced 
      HCC treated with LEN. METHODS: In this multicenter retrospective study, we 
      analyzed data on patient characteristics, treatment outcomes, and adverse events 
      (AEs) for 77 patients with advanced hepatocellular carcinoma (HCC). We also 
      analyzed PFS and factors that influence PFS. RESULTS: The response rate to LEN 
      was 29.9% and the disease control rate was 77.9%. Patients who achieved relative 
      dose intensities of more than 70% had better outcomes (response rate 45.2% vs. 
      11.4%, P < 0.01). Appetite loss, fatigue, diarrhea, hypertension, and thyroid 
      dysfunction were the most frequent AEs. Twenty-three patients (29.9%) had grade 3 
      or 4 AEs. Fifty-two patients (67.5%) required a dose reduction and 47 (61.0%) 
      stopped taking the drug due to AEs. The PFS rates at 3, 6, and 12 months were 
      81.2%, 49.8%, and 34.8%, respectively. The median PFS was 5.6 months. 
      Multivariate analysis showed that thyroid dysfunction of grade >/= 2 (hazard ratio 
      [HR] 4.57, 95% confidence interval [CI] 2.05-10.2, P < 0.01), appetite loss (HR 
      3.58, 95% CI 1.72-7.52, P < 0.01), and tumor diameter >/= 40 mm (HR: 2.27, 95% CI 
      1.17-4.40, P = 0.015) were independent factors associated with poor PFS. On the 
      other hand, Child-Pugh class 5A (HR 0.41, 95% CI 0.19-0.90, P = 0.027) and 
      complete or partial response (HR 0.40, 95% CI 0.17-0.95, P = 0.039) were 
      independent factors associated with better PFS. CONCLUSIONS: Thyroid dysfunction 
      and appetite loss after the administration of LEN were independent factors 
      associated with shorter PFS, so these AEs should be carefully managed after 
      administering LEN.
FAU - Ohki, Takamasa
AU  - Ohki T
AUID- ORCID: 0000-0003-4275-468X
AD  - Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, 
      Chiyoda-ku, Tokyo, 101-8643, Japan. anb72547@nifty.com.
FAU - Sato, Koki
AU  - Sato K
AD  - Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, 
      Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Kondo, Mayuko
AU  - Kondo M
AD  - Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, 
      Chiyoda-ku, Tokyo, 101-8643, Japan.
FAU - Goto, Eriko
AU  - Goto E
AD  - Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.
FAU - Sato, Takahisa
AU  - Sato T
AD  - Department of Gastroenterology, Teikyo University Medical Center, Chiba, Japan.
FAU - Kondo, Yuji
AU  - Kondo Y
AD  - Department of Gastroenterology and Hepatology, Kyoundo Hospital, Tokyo, Japan.
FAU - Akamatsu, Masatoshi
AU  - Akamatsu M
AD  - Department of Gastroenterology, JR Tokyo General Hospital, Tokyo, Japan.
FAU - Sato, Shinpei
AU  - Sato S
AD  - Department of Gastroenterology and Hepatology, Kyoundo Hospital, Tokyo, Japan.
FAU - Yoshida, Hideo
AU  - Yoshida H
AD  - Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan.
FAU - Koike, Yukihiro
AU  - Koike Y
AD  - Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.
FAU - Obi, Shuntaro
AU  - Obi S
AD  - Department of Gastroenterology, Teikyo University Medical Center, Chiba, Japan.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Drugs Real World Outcomes
JT  - Drugs - real world outcomes
JID - 101658456
PMC - PMC7221074
COIS- Takamasa Ohki has received speaking fees from Bayer Yakuhin and Eisai 
      Pharmaceutical Co., Ltd. The other authors have nothing to disclose.
EDAT- 2020/02/13 06:00
MHDA- 2020/02/13 06:01
PMCR- 2020/02/11
CRDT- 2020/02/13 06:00
PHST- 2020/02/13 06:00 [pubmed]
PHST- 2020/02/13 06:01 [medline]
PHST- 2020/02/13 06:00 [entrez]
PHST- 2020/02/11 00:00 [pmc-release]
AID - 10.1007/s40801-020-00179-7 [pii]
AID - 179 [pii]
AID - 10.1007/s40801-020-00179-7 [doi]
PST - ppublish
SO  - Drugs Real World Outcomes. 2020 Jun;7(2):141-149. doi: 
      10.1007/s40801-020-00179-7.